

Kent Academic Repository

Full text document (pdf)

Citation for published version

Dickinson, John W. and Amirav, Israel and Hostrup, Morten (2018) Nonpharmacologic Strategies to Manage Exercise-Induced Bronchoconstriction. *Immunology and Allergy Clinics of North America*, 38 (2). pp. 245-258. ISSN 0889-8561.

DOI

<https://doi.org/10.1016/j.iac.2018.01.012>

Link to record in KAR

<https://kar.kent.ac.uk/66974/>

Document Version

Author's Accepted Manuscript

Copyright & reuse

Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions for further reuse of content should be sought from the publisher, author or other copyright holder.

Versions of research

The version in the Kent Academic Repository may differ from the final published version.

Users are advised to check <http://kar.kent.ac.uk> for the status of the paper. **Users should always cite the published version of record.**

Enquiries

For any further enquiries regarding the licence status of this document, please contact:

researchsupport@kent.ac.uk

If you believe this document infringes copyright then please contact the KAR admin team with the take-down information provided at <http://kar.kent.ac.uk/contact.html>

1 **Manuscript title**

2 Non Pharmacological Strategies to Manage Exercise Induced Bronchoconstriction

3 John Dickinson¹, PhD, Israel Amirav², MD, and Morten Hostrup^{3,4}, PhD

- 4
- 5 1. School of Sport and Exercise Sciences, University of Kent, UK
- 6 2. Department of Paediatrics, University of Alberta, Edmonton, Canada
- 7 3. Department of Nutrition, Exercise and Sports, University of Copenhagen, Denmark,
- 8 mail: mhostrup@nexs.ku.dk
- 9 4. Department of Respiratory Medicine, Bispebjerg University Hospital, Denmark, mail:
- 10 mhostrup@nexs.ku.dk
- 11

12 **Disclosure statement**

13 Authors have no conflicting interests.

14

15 **SYNOPSIS (100 words)**

16 Pharmacological management of exercise induced bronchoconstriction (EIB) is the mainstay

17 of preventative therapy. However, there are some non-pharmacological interventions that may

18 assist the management of EIB. In this review we will discuss these non-pharmacological

19 interventions and how they may be applied to patients and athletes with EIB.

20

21 **KEY WORDS (4-8):**

22 **Warm-Up, Face Mask, Asthma, Pollution, Avoidance, Athletes, Nutrition, Training**

23

24

25

26 **KEY POINTS:**

- 27 • There is emerging evidence that non-pharmacological strategies can be used to
28 supplement traditional therapy to reduce exercise-induced bronchoconstriction (EIB)
29 severity and lessen respiratory symptoms associated with exercise
- 30 • Most investigations into non-pharmacological have included non-athletes,
31 extrapolating towards athletes should be done with caution and studies in athletes with
32 EIB are encouraged.
- 33 • There is currently insufficient evidence to support the use of any non-pharmacological
34 EIB treatment strategy in the absence of regular pharmaceutical therapy for EIB.

35

36 **INTRODUCTION**

37 Exercise-induced bronchoconstriction (EIB) is an asthma-related condition, which occurs
38 during or following exercise as a result of large volumes of ‘unconditioned air’ entering the
39 lower airways to meet the increased ventilatory demands of exercise^{1,2}. In susceptible
40 individuals, EIB arises via multiple mechanisms that may involve dehydration of airway
41 surface liquid, mucosal cooling and epithelial damage (ref to pathophysiology paper in series),
42 which induces an airway inflammatory response (involving histamine, neuropeptides,
43 leukotrienes and prostaglandins) with resultant airway smooth muscle constriction³.
44 Management of EIB in athletes is almost exclusively based around pharmacological therapies
45 (ref to pharmacological paper in series), such as glucocorticoids and β_2 -Agonists^{1,2}. Although
46 clinical data on non-pharmacological therapies has been equivocal, there is emerging evidence
47 that non-pharmacological strategies could be used to supplement traditional therapy to reduce
48 EIB severity and lessen exercise respiratory symptoms (table 1). This paper reviews the
49 evidence and provides recommendations for the use of non-pharmacological strategies in the
50 management of EIB.

Table 1. Non-pharmacological strategies to manage EIB

Strategy	Intervention	Potential effect	Evidence level	Pitfalls	References
Pre-exercise warm up	Repetitive 30-s bouts close to VO_{2max}/HR_{max}	Reduces post-exercise fall in FEV1	Good	May accumulate peripheral fatigue prior to exertion	5
Face masks	HME face masks	Reduces post-exercise fall in FEV1	Insufficient	May affect ventilation and be associated with discomfort	9-12
Omega-3 fatty acid supplementation	3 g/d EPA and 2 g/d DHA	Reduces systemic inflammation	Medium	Side effects: Acid reflux, bloating, diarrhea and nausea	34-37,40
		Reduces airway inflammation	Insufficient		
		Reduces post-exercise fall in FEV1	Insufficient		
Caffeine	5-10 mg/kgbw	Induces bronchodilation	Good	Slow absorption	47-52, 55-56
		Reduces post-exercise fall in FEV1	Medium	Side effects: Muscle tremors, tachycardia	
		Improves respiratory muscle fatigue resilience	Medium		
		Counteracts exercise-induced hypoxemia	Insufficient		
Vitamins and anti-oxidants	1500 mg/d vitamin C	Reduces systemic inflammation	Medium	Side effects: Diarrhea, vomiting, headache, insomnia, nausea, kidney stones	57-68
	64 mg/d β -carotene	Scavenge ROS	Medium		
		Reduces post-exercise fall in FEV1	Insufficient		
Breathing control	See table 2	Reduces perception of respiratory symptoms	Insufficient		69-72
Respiratory muscle training	30 breaths x 2/d at 50% of MIP	Improves respiratory muscle fatigue resilience	Good	Time-consuming	73-88
		Reduces asthma severity	Insufficient		

52 FEV1: forced expired volume in 1 s, HME: heat and moisture exchange, HR_{max} : maximal heart rate, MIP: maximal

53 inspiratory pressure, ROS: reactive oxygen species, VO_{2max} : maximal oxygen consumption

54 **PRE-EXERCISE WARM UP**

55 In approximately half of those who suffer from EIB, high intensity pre-exercise warm up
56 effectively protects against subsequent bronchoconstriction³. A recent systematic review⁴
57 reported that intermittent high intensity pre-exercise warm up (repetitive sprints of ~30 s close
58 to peak oxygen consumption or maximal HR) provides about 10% reduction in the fall in FEV₁
59 post exercise, whereas neither low intensity nor continuous high intensity pre exercise warm up
60 provides significant protection in individuals with EIB.

61 The refractory period or refractory effect, that is induced after a first exercise bout, has
62 frequently been proposed to explain why high intensity warm-ups protect against EIB. It has
63 been proposed that the first exercise induces a variable period (called the refractory period)
64 during which (2-4 hours) subsequent exercise will not result in EIB or will result in decreased
65 fall in FEV₁. As discussed by XXXXX (ref to refractory paper in this series), preceding exercise
66 may deplete constrictive mediators, induce secretion of protective mediators (particularly
67 prostaglandins) and cause desensitization of smooth muscle to bronchoconstrictive mediators³.
68 Regardless of the mechanism, there is good evidence to suggest a clinical benefit of warm ups
69 in protecting against EIB.

70

71 While high intensity exercise warm-ups may attenuate EIB³⁻⁴, the exercise intensity that is
72 required for the warm-up, may potentially cause perturbations in the exercising musculature
73 and compromise subsequent exercise performance⁵. However, emerging evidence suggests that
74 isolated respiratory warm-ups can provide similar bronchoprotective effects as whole-body
75 warm up⁶. Instead of using whole-body warm up, a recent study⁶ evaluated the effect of a
76 respiratory-only warm up on subsequent decline in FEV₁ induced by exhaustive cycling (\approx 14
77 min). In that study, subjects performed normocapnic hyperpnoea at different intensities (30-

78 80% of maximal voluntary ventilation). Notably, all hyperpnoea sessions attenuated post-
79 exercise decline in FEV₁ regardless of the intensity of the hyperpnoea session conducted and
80 without compromising cycling performance⁶. Perception of respiratory dyspnoea was also
81 reduced by preceding normocapnic hyperpnoea. Consequently, both pre-exercise whole body
82 and respiratory warm ups may be used to protect against EIB.

83

84 **AVOIDANCE OF TRIGGERS**

85 **Heat and Moisture Exchange Face Masks**

86 Exercise in dry and cold environments can be a significant trigger of bronchoconstriction (ref
87 to paper in series). The bronchoconstriction is thought to be caused by dehydration of the
88 airway surface liquid, which causes cell shrinkage, release of inflammatory mediators
89 precipitating airway smooth muscle constriction⁷. Repeated exposure of the airways to cold
90 dry air may also lead to airway epithelial cell damage, microvascular leakage and airway
91 remodelling, which may worsen asthma severity⁸. Given the increased risk of
92 bronchoconstriction in dry and cold environments, individuals with asthma may be advised to
93 avoid exercise outside. This places obvious constraints on athletes with asthma-related
94 conditions who have to train and complete in dry and cold environment and also the proportion
95 of individuals with asthma who engage in physical activity as part of their daily routines during
96 the winter months.

97

98 Face masks that incorporate a heat and moisture exchanger (HME) are a novel non-
99 pharmacological tool to counteract EIB in dry and cold environments. Although few studies
100 have investigated the efficacy of HME face masks in counteracting EIB, some studies have
101 demonstrated a protective effect as measured by an attenuation in post-exercise decline in
102 FEV₁⁹⁻¹². This suggests that individuals with asthma may use HME face masks to protect

103 against EIB when they engage in moderate to vigorous exercise in cold dry environments.
104 Currently, it is unknown whether the HME face masks reduce airway inflammation over acute
105 and multiple bouts of exercise. Nor is it known whether HME face masks reduce respiratory
106 symptoms and β_2 -Agonists usage over several weeks of engaging in exercise in dry cold
107 environments. If HME face masks are to be considered as part of a non-pharmaceutical therapy
108 plan, the design of the masks need to be considered, as individuals with asthma-related
109 conditions are unlikely to wear the masks if they find the masks large and cumbersome.
110 However, athletes may not see HME face masks as a viable strategy to prevent EIB as the
111 masks may not be practical wear to achieve optimal sporting performance or permitted by the
112 rules of the sport.

113

114 **Air pollution**

115 Air pollution has been shown to increase asthma severity and may have significant effects on
116 athletes due to the high ventilation rates they achieve and sustain during intense exercise¹³. Air
117 quality is inversely correlated with exercise-induced respiratory symptoms¹⁴. The risk is also
118 greater in those athletes who train on a regular basis in environments with poor air quality¹⁵.
119 Small particles, particularly ultra-fine ones (<100 nm diameter) like those from combustion
120 engines, have high lung deposition and may cause epithelial damage. These particles include
121 ozone (O₃), sulfur dioxide (SO₂), nitrogen oxides (NO_x) and particulate matter (PM_{2.5},
122 particles smaller than 2.5 mic diameter). Ice skaters are particularly exposed to combination of
123 cold dry air as well as PM₁ (PM < 1 mic diameter) in confined space of indoor ice arenas and
124 multiple ice-resurfacing by gas- or propane-powered machines. Particle inhalations have been
125 shown to induce oxidative stress, airway inflammation and airway remodelling. All these result
126 in higher prevalence of asthma symptoms, and great degree of small airway dysfunction¹⁶⁻¹⁹.

127

128 With regard to management, mechanical barriers, such as face masks, may help reduce the
129 effects of polluted particles⁹. Avoidance of training in low humidity conditions or during times
130 of high levels of atmospheric pollutants is advisable, yet its practical usage and scientific
131 benefit is still questionable. Similarly, whenever possible, it may be recommended to avoid
132 training close to busy major roadways or during rush hours or other times of elevated vehicular
133 congestion²⁰.

134

135 **Swimming**

136 The pathogenic mechanisms of EIB classically involve both osmolar and vascular changes in
137 the airways in addition to cooling of the airways^{2,7}. Increased minute ventilation during
138 exercise, requires significant warming and humidification of the inspired air. The resulting
139 respiratory heat and water loss from the airway mucosa into the inspired air may release
140 bronchoconstrictive mediators. In that respect, sports in warm humid environments, such as
141 indoor pools, are encouraged. Swimming has often been recommended as a less asthmogenic
142 trigger compared to other sports, because of the humid environment. Yet, a recent Cochrane
143 review concluded that there is insufficient evidence to suggest that aquatic-based exercise is
144 superior to comparative nonaquatic exercise in asthmatics²¹.

145

146 Chlorination is the most commonly used method for ensuring water hygiene in swimming
147 pools. Chlorine gas and its aerosol byproducts, (eg, trichloramine, hypochlorous acid, and
148 mono- and dichloramine), which float just above the water surface, may affect the nose,
149 pharynx, larynx trachea and bronchi with chronic exposure leading to structural epithelial
150 changes. During exercise, nasal breathing at rest shifts to oro-nasal breathing, thereby
151 significantly reducing the filtering effect of the nose. Aerosol particles travel and deposit
152 further into the lung. Trichloramine gas formed in chlorinated pools was suggested as a cause

153 for EIB in competitive swimmers and increased airway hyperreactivity (as measured by
154 methacholine or EVH challenge) has been demonstrated in swimmers where 43-68% of them
155 showed it²²⁻²⁴. Increasing evidence supports the notion that chronic repetitive swimming in
156 indoor pools may induce airway epithelial damage, inflammation, and remodelling²³⁻²⁵, and
157 increase the risk for atopy and asthma^{26,27}. A recent study found increased levels of 8-
158 isoprostane (8-IsoP) (as a marker of airway oxidative stress) in the exhale breath condensate of
159 competitive swimmers after a swimming session²⁷. Whenever possible, swimmers should train
160 in pools cleaned with non-chlorine water disinfection methods (such as copper/silver and
161 ozone) as well as in well ventilated pool environments. Yet, apart for some case reports²⁹, the
162 scientific evidence to support or refute many of these recommendations is lacking.

163

164 **DIETARY STRATEGIES**

165 **Omega-3 fatty acid supplementation**

166 It has been noted that populations who consume large quantities of oily fish have a lower
167 prevalence of asthma³⁰. Oily fish are rich in omega-3 fatty acids: eicosapentaenoic acid (EPA)
168 and docosahexaenoic acid (DHA). EPA and DHA are precursors to powerful agents involved
169 in the resolution of inflammation. Two mechanisms of action underpinning the anti-
170 inflammatory bio-actions include the ability of EPA to compete with arachidonic acid as a
171 substrate for cyclooxygenase (COX)-2 and 5-lipoxygenase (5-LO) enzymes and be converted
172 to less inflammatory leukotrienes and prostanoids³¹, and to generate the potent anti-
173 inflammatory E-series resolvins³¹. DHA may also alter gene transcription and translation via
174 direct or indirect actions on intracellular signalling pathways³³.

175

176 The anti-inflammatory properties of EPA and DHA make a diet high in oily fish an attractive
177 addition to the therapy of an individual with EIB. Initial investigations demonstrated 10 weeks

178 dietary supplementation of 3.2 g/d EPA and 2.2 g/d DHA reduced leukotriene production by
179 50%, but not reduction in post-exercise decline in FEV₁ in asthmatics³⁴. However, using the
180 same EPA and DHA dietary supplementation over a three week period, Mickleborough and
181 co-workers reported significant reductions in airway inflammation, which was accompanied
182 by 64-80% reductions in FEV₁ fall post exercise in individuals with EIB^{35,36}. Notably, post-
183 exercise decline in FEV₁, whilst on EPA and DHA supplementation, was similar to those of
184 the non-EIB control group. In addition, 3.2 g/d EPA and 2 g/d DHA were observed to be as
185 favourably as 10 mg/d montelukast in reducing airway inflammation and hyperpnoea-induced
186 bronchoconstriction in participants with mild to moderate persistent asthma³⁷. However, there
187 appears to be no additional benefit of combining EPA and DHA supplementation with 10 mg
188 montelukast³⁷. Furthermore, a recent pilot study found no beneficial effect of vitamin D and
189 fish oil supplementation for 3 weeks on reduction in FEV₁ induced by EVH in recreational
190 athletes with EIB³⁸.

191

192 Recently, the marine lipid fraction of the New Zealand green-lipped mussel (*Perna canaliculus*)
193 PCSO-524, which is rich in omega-3 fatty acids, has been shown to produce similar reductions
194 in inflammation and bronchoconstriction (57% reduction of FEV₁ fall) following a eucapnic
195 voluntary hyperpnoea challenge³⁹. In this investigation the attenuation of airway inflammation
196 and bronchoconstriction cannot be explained entirely by the EPA and DHA content of PCSO-
197 524, since the amount of EPA and DHA consumed daily was only 72 mg and 48 mg
198 respectively. Therefore, it may be that the additional constituents of PCSO-524 act
199 synergistically with EPA and DHA to bring about the anti-inflammatory effect and reduction
200 in bronchoconstriction.

201

202 While a low intake of EPA and DHA does not appear to be a safety issue a few side effects can
203 occur, such as a fishy aftertaste, flatulence, acid reflux, bloating, diarrhoea, nausea and possibly
204 an increased risk of bleeding and immunosuppression with a high intake of omega-3 fatty
205 acids⁴⁰. The initial investigations provide promise for EPA and DHA dietary supplementation
206 to protect against EIB and associated airway inflammation. However, large-scale clinical
207 studies in individuals with EIB are required to determine the minimum effective dose, duration
208 required to observe the beneficial effect and compare the effect of combining omega-3 fatty
209 acid supplementation with prevention inhaler therapy (e.g. inhaled glucocorticoids).

210

211 **Caffeine**

212 Caffeine (1,3,7-trimethylxanthine) is among the most commonly used supplements by
213 athletes⁴¹. While formerly being subjected to anti-doping regulations, the restrictions towards
214 caffeine were lifted by the World Anti-Doping Agency (WADA) in 2004 and can as such be
215 used freely in and out of competition. Caffeine works as a non-selective competitive adenosine
216 receptor antagonist for all subtypes of the adenosine receptor^{42,43}, but may also act as a
217 phosphodiesterase inhibitor⁴⁴. Accordingly, caffeine induces intracellular cAMP-
218 dependent/protein kinase A signalling, which like β_2 -Agonists, causes smooth muscle
219 relaxation⁴⁵. Indeed, studies have shown dose-related bronchodilator effects of caffeine on
220 basal airway function⁴⁶. The interest in caffeine as a bronchoprotective agent started some 30
221 years ago when Becker and co-workers (1984) observed that 10 mg/kg_{bw} of orally ingested
222 caffeine had a similar bronchodilating effect as 5 mg/kg_{bw} oral theophylline in children with
223 asthma⁴⁷. Comparable bronchodilating effect was later shown in adult asthma patients after
224 ingestion of 5 mg/kg_{bw} caffeine⁴⁷ or 3 cups of coffee⁴⁹.

225

226 Although caffeine shows promise as a bronchodilator, only a few studies have investigated its
227 potential to counteract EIB of which none have been performed in athletes. In non-athletes,
228 ingestion of caffeine was shown to have a post-exercise bronchoprotective effect compared to
229 placebo in individuals with EIB⁵⁰. While post-exercise decline in FEV₁ was 24% for placebo,
230 it was less than 1% after ingestion of 7 mg/kg_{bw} caffeine and 8% after 3 mg/kg_{bw} caffeine. In
231 accordance with this observation, Duffy & Phillips (1991) observed that ingestion of 10
232 mg/kg_{bw} caffeine reduced bronchoconstrictor response to EVH-provocation compared to
233 placebo in EVH-positive individuals⁵¹. When compared to inhalation of β_2 -Agonist salbutamol
234 (180 mg albuterol), ingestion of 9 mg/kg_{bw} caffeine was shown to be as effective as salbutamol
235 in attenuating post-exercise reduction in FEV₁ in asthmatics with EIB⁵².

236

237 Aside from its bronchoprotective effect, caffeine has a variety of other effects of relevance for
238 airway function during exercise. During submaximal exercise, as little as 3 mg/kg_{bw} oral
239 caffeine has been shown to modulate ventilatory dynamics by reducing the physiological dead
240 space ventilation/tidal volume ratio and breathing frequency, while concurrently increasing
241 tidal volume^{53,54}. In addition, caffeine may counteract exercise-induced hypoxemia
242 (desaturation) in elite athletes at submaximal intensities⁵⁵ and improve respiratory muscle
243 fatigue resilience⁵⁶.

244

245 Despite the small number of studies undertaken, there is some evidence to suggest that caffeine
246 has the potential to reduce EIB severity and improve ventilatory dynamics and respiratory
247 muscle fatigue resilience during exercise. The amount of orally ingested caffeine needed for
248 bronchoprotection is approximately 5-10 mg/kg_{bw}, which would be equivalent to 2-4 cups of
249 coffee. However, it appears that the bronchoprotective effect of caffeine is highly individual.
250 A limitation of caffeine is the slow absorption rate when ingested, giving rise to a

251 bronchodilator response 2 hours after ingestion. Future studies should investigate more
252 thoroughly the therapeutic efficacy of caffeine as a bronchoprotective substance during
253 exercise in athletes with EIB.

254

255 **Vitamins and anti-oxidants**

256 Supplementation with various vitamins and anti-oxidants has attracted some attention as means
257 to counteract EIB because of their ability to suppress proinflammatory signalling⁵⁷, to lower
258 levels of histamine^{58,59} and prostaglandin F_{2α}⁶⁰, and to scavenge reactive oxygen species
259 (ROS)^{61,62}. In practical terms, however, interpretation of the therapeutic efficacy of each
260 individual vitamin and anti-oxidant as bronchoprotective substances in EIB is limited by the
261 small number of studies that have been undertaken in individuals with EIB, especially in
262 athletes. Most convincing is the bronchoprotective effect of acute and chronic supplementation
263 with vitamin C on post-exercise decline in FEV₁ in individuals with EIB^{60,63-65}. In addition,
264 one week supplementation with β-carotene (64 mg), a provitamin A carotenoid, has been
265 shown to reduce post-exercise reduction in FEV₁⁶⁶. Conflicting results have been observed
266 after one week supplementation with the carotenoid lycopene (30 mg), in which a post-exercise
267 bronchoprotective effect was found in asthmatic individuals with EIB, whereas adolescent
268 athletes with EIB had no effect^{67,68}.

269

270 **STRATEGIES TO REDUCE PERCEPTION OF EXERTIONAL DYSPNOEA**

271 Above we have discussed strategies that may help control EIB. In addition, there may also be
272 a role for utilising breathing control and inspiratory muscle training in order enable athletes
273 with EIB to reduce perceptions of exertional dyspnoea.

274

275

276 **Breathing control**

277 A significant symptom of EIB is dyspnoea during and after exercise. There are a variety of
278 breathing exercises that may benefit individuals who experience asthma/EIB exacerbations that
279 include yogic breathing⁶⁹⁻⁷¹ and physiotherapist-supervised breathing training⁷². Although
280 these forms of breathing control exercises may not be able to reduce asthma severity they may
281 be able to reduce the perception of respiratory symptoms and increase perception of asthma
282 control⁶⁹. Moreover, breathing exercises have been shown to improve quality of life⁷⁰, reduce
283 use of relief medication⁷⁰, reduce the levels of anxiety and depression⁷² and airway
284 hyperresponsiveness⁷¹. Future research is required to understand the mechanisms behind these
285 observations in asthmatic individuals.

286

287 It is currently unknown how these forms of breathing control exercises may be beneficial for
288 athletes with EIB, whose main symptoms are experienced during exercise. However, the use
289 of breathing training incorporating, inspiratory muscle training and breathing technique
290 training (table 2), has been shown to be helpful in reducing the perception of breathing in an
291 athlete with non-asthmatic exercise respiratory conditions⁷³. Future research is required to
292 investigate how athletes with EIB respond to using breathing exercises. Furthermore, the
293 current breathing control methods may need to be adapted to replicate respiratory control
294 during exercise rather than focusing on breathing control at rest.

295

296

297

298

299

300

301 Table 2: Summary of breathing training for athletes

Breathing Control Methods	Overview
Breathing Technique	Encourage initiation of inspiration from the lower rib cage. Inspiratory manoeuvre should be smooth with little tension through the shoulders and neck. Aids such as elastic strap or hands placed on sides of torso over lower ribs can be used to help athletes. Athlete can begin to attempt to practice this technique in functional sport specific positions
Inspiratory Muscle Training (IMT)	Ensure breathing technique is addressed before initiating IMT. Athletes with poor breathing technique, who proceed directly to IMT, may experience exacerbation of their symptoms. IMT should incorporate forceful inspiratory manoeuvres through a hand-held device providing resistance to the inspired airflow. Focus during the IMT should be on good breathing technique (as described above). An IMT session should comprise of 30 continuous forced inspiratory efforts at the equivalent of 30 breath repetition maximum, with relaxed expiration.

302 Adapted from Dickinson, J. McConnell A. Ross E. Brown, P. Hull, J. Assessment and
 303 Management of Non-Asthma Related Breathing Problems in Athletes. The Sport and Exercise
 304 Scientist. 2015; 45: 8-9

305

306 **Respiratory Muscle Training**

307 Respiratory muscle training is an easy and cheap way to enhance both inspiratory and
 308 expiratory muscle strength⁷⁴, and has also been associated with improvements in exercise

309 performance during various exercise protocols in healthy individuals^{75,76}. However, despite
310 decades of research into the applications of respiratory muscle training, the area is still
311 controversial and subject to scientific debate⁷⁷⁻⁷⁹. Respiratory muscle training has shown some
312 promise in the management of chronic obstructive pulmonary disease⁸⁰, inspiratory stridor⁷³
313 and exercise-induced vocal cord dysfunction^{81,82}. However, although studies also have shown
314 that respiratory muscle training may have beneficial effects on asthma severity and beta₂-
315 agonist usage⁸³⁻⁸⁵, a recent cochrane review, based on 113 asthmatics, concluded that there is
316 no conclusive evidence to support or refute the therapeutic efficacy of inspiratory muscle
317 training in asthma⁸⁶. Nevertheless, given individuals with EIB may experience airway
318 obstruction and airflow limitation during intense exercise⁸⁷, which potentially puts a larger
319 work load on respiratory muscles^{3,88}, it could be speculated that respiratory muscle training
320 may be beneficial for athletes with EIB. However, to our knowledge, no studies have
321 investigated the effectiveness of respiratory muscle training on EIB severity⁸⁹.

322

323 **SUMMARY AND FUTURE CONSIDERATIONS**

324 There are numerous non-pharmacological strategies that can be utilised to support the treatment
325 of EIB, however the evidence is inconclusive and future studies are encouraged before any
326 recommendations are implemented. There is currently insufficient evidence to support the use
327 of any non-pharmacological EIB treatment strategy in the absence of regular pharmaceutical
328 therapy for EIB. While there is some encouraging findings with regards to nutritional
329 supplementation and respiratory muscle training, future studies are encouraged, especially in
330 athletes. Most studies have included non-athletes and extrapolation towards athletes should
331 therefore be done with caution. Furthermore, data on other commonly used supplements by
332 athletes, such as beta-alanine and creatine are lacking in relation to EIB. For instance, beta-

333 alanine supplementation increases intracellular content of carnosine, which among other
334 factors⁹⁰, may affect nitric oxide production and modulate inflammation^{91,92}, both of which
335 could affect EIB severity. In addition, creatine supplementation has been shown to exacerbate
336 airway inflammation, increase airway hyperresponsiveness and induce smooth muscle
337 thickening in mice⁹³. However, no studies, have to our knowledge, investigated the effect of
338 creatine supplementation on EIB severity in athletes. Consequently, there are numerous non-
339 pharmacological strategies yet to be studied in athletes with EIB.

340

341 **REFERENCES**

- 342 1. Fitch KD, Sue-Chu M, Anderson SD, Boulet LP, Hancox RJ, McKenzie DC, Backer V,
343 Rundell KW, Alonso JM, Kippelen P, Cummiskey JM, Garnier A, Ljungqvist A. Asthma and
344 the elite athlete: summary of the International Olympic Committee's consensus conference,
345 Lausanne, Switzerland, January 22-24, 2008. *J Allergy Clin Immunol.* 2008; 122(2):254-60
- 346 2. Price OJ, Hull JH, Backer V, Hostrup M, Ansley L. The impact of exercise-induced
347 bronchoconstriction on athletic performance: a systematic review. *Sports Med.* 2014 ;
348 44(12):1749-61.
- 349 3. Larsson J, Anderson SD, Dahlén SE, Dahlén B. Refractoriness to exercise challenge: a
350 review of the mechanisms old and new. *Immunol Allergy Clin North Am.* 2013; 33(3): 329-5.
- 351 Stickland MK, Rowe BH, Spooner CH, Vandermeer B, Dryden DM. Effect of warm-up
352 exercise on exercise-induced bronchoconstriction. *Med Sci Sports Exerc.* 2012; 44(3): 383-91.
- 353 5. Hostrup M, Bangsbo J. Limitations in intense exercise performance of athletes - effect of
354 speed endurance training on ion handling and fatigue development. *J Physiol.* 2017; 595(9):
355 2897-2913.
- 356 6. Eichenberger PA, Scherer TA, Spengler CM. Pre-Exercise Hyperpnea Attenuates Exercise-
357 Induced Bronchoconstriction Without Affecting Performance. Loukides S, ed. *PLoS ONE.*
358 2016; 11(11): e0167318. doi:10.1371/journal.pone.0167318.

- 359 7. Anderson SD, Kippelen P. Airway injury as a mechanism for exercise-induced
360 bronchoconstriction in elite athletes. *J Allergy Clin Immunol.* 2008 Aug; 122(2): 225-35.
- 361 8. Karjalainen, E., Laitinen, A., Sue-Chu, M., Altraja, A., Bjermer, L. & Laitinen, L. Evidence
362 of airway inflammation and remodeling in ski athletes with and without bronchial
363 hyperresponsiveness to methacholine. *Am J Respir Crit Care Med.* 2000. 161, 2086-91.
- 364 9. Beuther DA, Martin RJ. Efficacy of a heat exchanger mask in cold exercise-induced asthma.
365 *Chest.* 2006; 129(5): 1188-93.
- 366 10. Brenner, A., Weiser, P., Krogh, L. & Loren, M. (1980) Effectiveness of a portable face
367 mask in attenuating exercise-induced asthma. *JAMA.* 1980; 244: 2196-8.
- 368 11. Millqvist E., Bengtsson U. Löwhagen O. Combining a beta2-agonist with a face mask to
369 prevent exercise-induced bronchoconstriction. *Allergy.* 2000; 55: 672-5.
- 370 12. Nisar M. Spence D. West D. Haycock J. Jones Y. Walshaw M. Earis J. Calverley P. Pearson
371 M. A mask to modify inspired air temperature and humidity and its effect on exercise induced
372 asthma. *Thorax.* 1992; 47: 446-50.
- 373 13. Guarnieri M. Balmes J. Outdoor air pollution and asthma. *The Lancet.* 2014; 383: 1581-
374 1592
- 375 14. Rundell KW, Spiering BA, Judelson DA, Wilson MH. Bronchoconstriction during cross-
376 country skiing: is there really a refractory period? *Med Sci Sports Exerc.* 2003; 35(1): 18-26.
- 377 15. Bernard A, Nickmilder M, Voisin C. Outdoor swimming pools and the risks of asthma and
378 allergies during adolescence. *Eur Respir J.* 2008; 32(4): 979-88.
- 379 16. Lumme A, Haahtela T, Ounap J, Ryttilä P, Obase Y, Helenius M, Remes V, Helenius I.
380 Airway inflammation, bronchial hyperresponsiveness and asthma in elite ice hockey players.
381 *Eur Respir J.* 2003; 22(1): 113-7.
- 382 17. Rundell KW, Spiering BA, Evans TM, Baumann JM. Baseline lung function, exercise-
383 induced bronchoconstriction, and asthma-like symptoms in elite women ice hockey players.
384 *Med Sci Sports Exerc.* 2004; 36(3): 405-10.

- 385 18. Rundell KW, Im J, Mayers LB, Wilber RL, Szmedra L, Schmitz HR. Self-reported
386 symptoms and exercise-induced asthma in the elite athlete. *Med Sci Sports Exerc.* 2001; 33(2):
387 208-13.
- 388 19. Rundell KW, Caviston R, Hollenbach AM, Murphy K. Vehicular air pollution,
389 playgrounds, and youth athletic fields. *Inhal Toxicol.* 2006; 18(8): 541-7
- 390 20. Cutrufello PT, Smoliga JM, Rundell KW. Small things make a big difference: particulate
391 matter and exercise. *Sports Med.* 2012; 42(12): 1041-58.
- 392 21. Silva GAJ, Andriolo BNG, Riera R, Parra SA, Peccin MS. Water-based exercise for adults
393 with asthma (review) *Cochrane Database Syst Rev.* 2014;7:CD003316, 1–36.
- 394 22. Levai IK, Hull JH, Loosemore M, Greenwell J, Whyte G, Dickinson JW. Environmental
395 influence on the prevalence and pattern of airway dysfunction in elite athletes. *Respirology.*
396 2016; 21(8): 1391-1396.
- 397 23. Bougault V, Boulet LP. Is there a potential link between indoor chlorinated pool
398 environment and airway remodeling/inflammation in swimmers? *Expert Rev Respir Med.*
399 2012; 6(5): 469-71.
- 400 24. Bougault V, Loubaki L, Joubert P, Turmel J, Couture C, Laviolette M, Chakir J, Boulet
401 LP. Airway remodeling and inflammation in competitive swimmers training in indoor
402 chlorinated swimming pools. *J Allergy Clin Immunol.* 2012; 129(2): 351-8.
- 403 25. Sue-Chu M. Winter sports athletes: long-term effects of cold air exposure. *Br J Sports Med.*
404 2012; 46(6): 397-401.
- 405 26. Bernard A, Carbonnelle S, de Burbure C, Michel O, Nickmilder M. Chlorinated pool
406 attendance, atopy, and the risk of asthma during childhood. *Environ Health Perspect.* 2006;
407 114(10): 1567-73.
- 408 27. Bernard A, Carbonnelle S, Michel O, Higuët S, De Burbure C, Buchet JP, Hermans C,
409 Dumont X, Doyle I. Lung hyperpermeability and asthma prevalence in schoolchildren:
410 unexpected associations with the attendance at indoor chlorinated swimming pools. *Occup*
411 *Environ Med.* 2003; 60(6): 385-94.

- 412 28. Morissette MC, Murray N, Turmel J, Milot J, Boulet LP, Bougault V. Increased exhaled
413 breath condensate 8-isoprostane after a swimming session in competitive swimmers. *Eur J*
414 *Sport Sci.* 2016; 16(5): 569-576.
- 415 29. Beretta S, Vivaldo T, Morelli M, Carlucci P, Zuccotti GV. Swimming pool-induced asthma.
416 *J Investig Allergol Clin Immunol.* 2011; 21(3): 240-1.
- 417 30. Horrobin D. Low prevalences of coronary heart disease (CHD), psoriasis, asthma and
418 rheumatoid arthritis in Eskimos: are they caused by high dietary intake of eicosapentaenoic
419 acid (EPA), a genetic variation of essential fatty acid (EFA) metabolism or a combination of
420 both? *Med Hypotheses.* 1987; 22(4): 421-8
- 421 31. Thien F, Hallsworth M, Soh C, Lee T. Effects of exogenous eicosapentaenoic acid on
422 generation of leukotriene C4 and leukotriene C5 by calcium ionophore-activated human
423 eosinophils in vitro. *J Immunol.* 1993; 150: 3546-52.
- 424 32. Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, Oh SF, Spite M.
425 Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions.
426 *J Exp Med.* 2009;206(1): 15-23.
- 427 33. Weldon S, Mullen A, Loscher C, Hurley L, Roche H. Docosahexaenoic acid induces an
428 anti-inflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages more
429 effectively than eicosapentaenoic acid. *J Nutr Biochem.* 2007; 18(4): 250-8.
- 430 34. Arm JP, Horton CE, Mencia-Huerta JM, House F, Eiser NM, Clark TJ, Spur BW, Lee TH.
431 Effect of dietary supplementation with fish oil lipids on mild asthma. *Thorax.* 1988; 43(2): 84-
432 92.
- 433 35. Mickleborough TD, Murray RL, Ionescu AA, Lindley MR. Fish oil supplementation
434 reduces severity of exercise-induced bronchoconstriction in elite athletes. *Am J Respir Crit*
435 *Care Med.* 2003; 168(10): 1181-9.
- 436 36. Mickleborough TD, Lindley MR, Ionescu AA, Fly AD. Protective effect of fish oil
437 supplementation on exercise-induced bronchoconstriction in asthma. *Chest.* 2006; 129(1): 39-
438 49.

- 439 37. Tecklenburg-Lund S, Mickleborough TD, Turner LA, Fly AD, Stager JM, Montgomery
440 GS. Randomized controlled trial of fish oil and montelukast and their combination on airway
441 inflammation and hyperpnea-induced bronchoconstriction. *PLoS One*. 2010; 5(10): e13487.
- 442 38. Price OJ, Hull JH, Howatson G, Robson-Ansley P, Ansley L. Vitamin D and omega-3
443 polyunsaturated fatty acid supplementation in athletes with exercise-induced
444 bronchoconstriction: a pilot study. *Expert Rev Respir Med*. 2015; 9(3): 369-78
- 445 39. Mickleborough TD, Vaughn CL, Shei RJ, Davis EM, Wilhite DP. Marine lipid fraction
446 PCSO-524 (lyprinol/omega XL) of the New Zealand green lipped mussel attenuates
447 hyperpnea-induced bronchoconstriction in asthma. *Respir Med*. 2013; 107(8): 1152-63.
- 448 40. Mickleborough TD, Lindley MR. Omega-3 fatty acids: a potential future treatment for
449 asthma? *Expert Rev Respir Med*. 2013; 7(6): 577-80.
- 450 41. Del Coso J, Muñoz G, Muñoz-Guerra J. Prevalence of caffeine use in elite athletes
451 following its removal from the World Anti-Doping Agency list of banned substances. *Appl*
452 *Physiol Nutr Metab*. 2011;36(4): 555-61.
- 453 42. Evoniuk G, Jacobson KA, Shamim MT, Daly JW, Wurtman RJ. A1- and A2-selective
454 adenosine antagonists: in vivo characterization of cardiovascular effects. *J Pharmacol Exp*
455 *Ther*. 1987; 242(3): 882-7.
- 456 43. Snyder SH, Katims JJ, Annau Z, Bruns RF, Daly JW. Adenosine receptors and behavioral
457 actions of methylxanthines. *Proc Natl Acad Sci U S A*. 1981; 78(5): 3260-4.
- 458 44. Rivedal E, Sanner T. Caffeine and other phosphodiesterase inhibitors are potent inhibitors
459 of the promotional effect of TPA on morphological transformation of hamster embryo cells.
460 *Cancer Lett*. 1985; 28(1): 9-17.
- 461 45. Niewoehner DE, Campe H, Duane S, McGowan T, Montgomery MR. Mechanisms of
462 airway smooth muscle response to isoproterenol and theophylline. *J Appl Physiol Respir*
463 *Environ Exerc Physiol*. 1979; 47(2): 330-6.
- 464 46. Welsh EJ, Bara A, Barley E, Cates CJ. Caffeine for asthma. *Cochrane Database Syst Rev*.
465 2010; (1): CD001112.

- 466 47. Becker AB, Simons KJ, Gillespie CA, Simons FER. The bronchodilator effects and
467 pharmacokinetics of caffeine in asthma. *N Eng J Med* 1984; 310:743-46.
- 468 48. Bukowskyj M, Nakatsu K. The bronchodilator effect of caffeine in adult asthmatics. *Am*
469 *Rev Respir Dis.* 1987; 135(1): 173-5.
- 470 49. Gong H Jr, Simmons MS, Tashkin DP, Hui KK, Lee EY. Bronchodilator effects of caffeine
471 in coffee. *Chest.* 1986; 89: 335-42.
- 472 50. Kivity S, Ben Aharon Y, Man A, Topilsky M. The effect of caffeine on exercise-induced
473 bronchoconstriction. *Chest.* 1990; 97(5): 1083-5.
- 474 51. Duffy P, Phillips YY. Caffeine consumption decreases the response to bronchoprovocation
475 challenge with dry gas hyperventilation. *Chest.* 1991; 99(6): 1374-7.
- 476 52. VanHaitisma TA, Mickleborough T, Stager JM, Koceja DM, Lindley MR, Chapman R.
477 Comparative effects of caffeine and albuterol on the bronchoconstrictor response to exercise
478 in asthmatic athletes. *Int J Sports Med.* 2010; 31(4): 231-6.
- 479 53. Birnbaum LJ, Herbst JD. Physiologic effects of caffeine on cross-country runners. *J*
480 *Strength Cond Res.* 2004; 18(3): 463-5.
- 481 54. Brown DD, Knowlton RG, Sullivan JJ, Sanjabi PB. Effect of caffeine ingestion on alveolar
482 ventilation during moderate exercise. *Aviat Space Environ Med.* 1991; 62(9 Pt 1): 860-4.
- 483 55. Chapman RF, Stager JM. Caffeine stimulates ventilation in athletes with exercise-induced
484 hypoxemia. *Med Sci Sports Exerc.* 2008; 40(6): 1080-6.
- 485 56. Supinski GS, Levin S, Kelsen SG. Caffeine effect on respiratory muscle endurance and
486 sense of effort during loaded breathing. *J Appl Physiol.* 1986; 60(6): 2040-7.
- 487 57. Jiang Q. Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory
488 activities and their role in disease prevention and therapy. *Free Radic Biol Med.* 2014; 72: 76-
489 90.
- 490 58. Johnston CS, Retrum KR, Srilakshmi JC. Antihistamine effects and complications of
491 supplemental vitamin C. *J Am Diet Assoc.* 1992; 92(8): 988-9.

- 492 59. Johnston CS, Solomon RE, Corte C. Vitamin C depletion is associated with alterations in
493 blood histamine and plasma free carnitine in adults. *J Am Coll Nutr.* 1996; 15(6): 586-91.
- 494 60. Tecklenburg SL, Mickleborough TD, Fly AD, Bai Y, Stager JM. Ascorbic acid
495 supplementation attenuates exercise-induced bronchoconstriction in patients with asthma.
496 *Respir Med.* 2007; 101(8): 1770-8.
- 497 61. Traber MG, Stevens JF; Stevens. Vitamins C and E: Beneficial effects from a mechanistic
498 perspective. *Free Radical Bio Med* 2011; 51 (5): 1000–13.
- 499 62. Ashton T, Young IS, Peters JR, Jones E, Jackson SK, Davies B, Rowlands CC. Electron
500 spin resonance spectroscopy, exercise, and oxidative stress: an ascorbic acid intervention study.
501 *J Appl Physiol.* 1999; 87(6): 2032-6.
- 502 63. Schachter EN, Schlesinger A. The attenuation of exercise-induced bronchospasm by
503 ascorbic acid. *Ann Allergy.* 1982; 49(3): 146-51.
- 504 64. Cohen HA, Neuman I, Nahum H. Blocking effect of vitamin C in exercise-induced asthma.
505 *Arch Pediatr Adolesc Med.* 1997; 151(4): 367-70.
- 506 65. Hemilä H. The effect of vitamin C on bronchoconstriction and respiratory symptoms caused
507 by exercise: a review and statistical analysis. *Allergy Asthma Clin Immunol.* 2014; 10(1): 58.
- 508 66. Neuman I, Nahum H, Ben-Amotz A. Prevention of exercise-induced asthma by a natural
509 isomer mixture of beta-carotene. *Ann Allergy Asthma Immunol.* 1999; 82(6): 549-53.
- 510 67. Neuman I, Nahum H, Ben-Amotz A. Reduction of exercise-induced asthma oxidative stress
511 by lycopene, a natural antioxidant. *Allergy.* 2000; 55(12): 1184-9.
- 512 68. Falk B, Gorev R, Zigel L, Ben-Amotz A, Neuman I. Effect of lycopene supplementation
513 on lung function after exercise in young athletes who complain of exercise-induced
514 bronchoconstriction symptoms. *Ann Allergy Asthma Immunol.* 2005; 94(4): 480-5.
- 515 69. Karam M, Kaur B, Baptist A. A modified breathing exercise program for asthma is easy to
516 perform and effective. *J Asthma.* 2017; 54(2): 217-222

- 517 70. Vempati R, Bijlani RL, Deepak KK. The efficacy of a comprehensive lifestyle modification
518 programme based on yoga in the management of bronchial asthma: a randomized controlled
519 trial. *BMC Pulm Med.* 2009; 9: 37.
- 520 71. Manocha R, Marks G, Kenchington P, Peters D, Salome C. Sahaja yoga in the management
521 of moderate to severe asthma: a randomised controlled trial. *Thorax.* 2002; 57(2): 110-5.
- 522 72. Thomas M, McKinley RK, Mellor S, Watkin G, Holloway E, Scullion J, Shaw DE,
523 Wardlaw A, Price D, Pavord I. Breathing exercises for asthma: a randomised controlled trial.
524 *Thorax.* 2009; 64(1): 55-61.
- 525 73. Dickinson J, Whyte G, McConnell A. Inspiratory muscle training: a simple cost-effective
526 treatment for inspiratory stridor. *Br J Sports Med.* 2007; 41(10): 694-5.
- 527 74. Romer LM, McConnell AK. Specificity and reversibility of inspiratory muscle training.
528 *Med Sci Sports Exerc.* 2003; 35(2): 237-44.
- 529 75. Kilding AE, Brown S, McConnell AK. Inspiratory muscle training improves 100 and 200
530 m swimming performance. *Eur J Appl Physiol.* 2010; 108(3): 505-11.
- 531 76. Illi SK, Held U, Frank I, Spengler CM. Effect of respiratory muscle training on exercise
532 performance in healthy individuals: a systematic review and meta-analysis. *Sports Med.* 2012;
533 42(8): 707-24.
- 534 77. McConnell AK. CrossTalk opposing view: respiratory muscle training does improve
535 exercise tolerance. *J Physiol.* 2012; 590(15): 3397-8.
- 536 78. Mickleborough TD, Stager JM, Chatham K, Lindley MR, Ionescu AA. Pulmonary
537 adaptations to swim and inspiratory muscle training. *Eur J Appl Physiol.* 2008; 103(6): 635-
538 46.
- 539 79. Patel MS, Hart N, Polkey MI. CrossTalk proposal: training the respiratory muscles does
540 not improve exercise tolerance. *J Physiol.* 2012; 590(15): 3393-5.
- 541 80. Geddes EL, O'Brien K, Reid WD, Brooks D, Crowe J. Inspiratory muscle training in adults
542 with chronic obstructive pulmonary disease: an update of a systematic review. *Respir Med.*
543 2008; 102(12): 1715-29.

- 544 81. Mathers-Schmidt BA, Brilla LR. Inspiratory muscle training in exercise-induced
545 paradoxical vocal fold motion. *J Voice*. 2005; 19(4): 635-44.
- 546 82. Ruddy BH, Davenport P, Baylor J, Lehman J, Baker S, Sapienza C. Inspiratory muscle
547 strength training with behavioral therapy in a case of a rower with presumed exercise-induced
548 paradoxical vocal-fold dysfunction. *Int J Pediatr Otorhinolaryngol*. 2004; 68(10): 1327-32.
- 549 83. Turner LA, Mickleborough TD, McConnell AK, Stager JM, Tecklenburg-Lund S, Lindley
550 MR. Effect of inspiratory muscle training on exercise tolerance in asthmatic individuals. *Med
551 Sci Sports Exerc*. 2011; 43(11): 2031-8.
- 552 84. Weiner P, Azgad Y, Ganam R, Weiner M. Inspiratory muscle training in patients with
553 bronchial asthma. *Chest*. 1992; 102(5): 1357-61.
- 554 85. Weiner P, Berar-Yanay N, Davidovich A, Magadle R, Weiner M. Specific inspiratory
555 muscle training in patients with mild asthma with high consumption of inhaled beta(2)-
556 agonists. *Chest*. 2000; 117(3): 722-7.
- 557 86. Silva IS, Fregonezi GA, Dias FA, Ribeiro CT, Guerra RO, Ferreira GM. Inspiratory muscle
558 training for asthma. *Cochrane Database Syst Rev*. 2013; (9):CD003792.
- 559 87. Johnson BD, Scanlon PD, Beck KC. Regulation of ventilatory capacity during exercise in
560 asthmatics. *J Appl Physiol*. 1995; 79(3): 892-901.
- 561 88. Kosmas EN, Milic-Emili J, Polychronaki A, Dimitroulis I, Retsou S, Gaga M, Koutsoukou
562 A, Roussos Ch, Koulouris NG. Exercise-induced flow limitation, dynamic hyperinflation and
563 exercise capacity in patients with bronchial asthma. *Eur Respir J*. 2004; 24(3): 378-84.
- 564 89. Shei RJ, Paris HL, Wilhite DP, Chapman RF, Mickleborough TD. The role of inspiratory
565 muscle training in the management of asthma and exercise-induced bronchoconstriction. *Phys
566 Sportsmed*. 2016; 44(4): 327-334.
- 567 90. Hostrup M, Bangsbo J. Improving beta-alanine supplementation strategy to enhance
568 exercise performance in athletes. *J Physiol*. 2016; 594(17): 4701-2.
- 569 91. Severina IS, Bussygina OG, Pyatakova NV. Carnosine as a regulator of soluble guanylate
570 cyclase. *Biochemistry (Mosc)*. 2000; 65(7): 783-8.

571 92. Caruso G, Fresta CG, Martinez-Becerra F, Antonio L, Johnson RT, de Campos RP, Siegel
572 JM, Wijesinghe MB, Lazzarino G, Lunte SM. Carnosine modulates nitric oxide in stimulated
573 murine RAW 264.7 macrophages. *Mol Cell Biochem.* 2017 Mar 13. doi: 10.1007/s11010-017-
574 2991-3.

575 93. Vieira RP, Duarte AC, Claudino RC, Perini A, Santos AB, Moriya HT, Arantes-Costa FM,
576 Martins MA, Carvalho CR, Dolhnikoff M. Creatine supplementation exacerbates allergic lung
577 inflammation and airway remodeling in mice. *Am J Respir Cell Mol Biol.* 2007; 37(6): 660-7.